報價延遲最少15分鐘:2025/06/02 05:41 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3446 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.59/-1.82
|
|
企業價值
55.74M
|
| 資產負債 |
|
每股賬面淨值
-0.25
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
40.50M
|
|
每股收益
0.33
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 05:41 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175. |